GANTANOL
LOE ApproachingNDAORALSUSPENSION
Approved
Jul 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 35m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GANTANOL is an oral suspension small-molecule drug approved by Roche in 1965. The generic name and mechanism of action are not publicly documented in available records. This legacy product represents a mature therapeutic asset with approaching loss of exclusivity.
LOE Approaching
Product is in late-stage lifecycle with minimal commercial investment signals; team likely focused on retention and operational efficiency rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GANTANOL offers limited career growth opportunities due to its LOE-approaching status and minimal linked job openings. Roles on this product are primarily defensive, focused on managing decline and optimizing operations rather than driving innovation or commercial expansion.
Brand ManagerProduct Manager
Worked on GANTANOL at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.